clear cell
Showing 1 - 25 of >10,000
Ovarian Clear Cell Carcinoma Trial in Houston (Dostarlimab, LB-100)
Not yet recruiting
- Ovarian Clear Cell Carcinoma
-
Houston, TexasM D Anderson Cancer Center
Sep 26, 2023
Moesin Expression in Clear Cell Renal Cell Carcinoma
Completed
- Renal Cell Carcinoma
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- (no location specified)
Sep 20, 2023
Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)
Not yet recruiting
- Ovarian Clear Cell Carcinoma
- Zimberelimab
- Metformin Hydrochloride
- (no location specified)
Feb 25, 2023
Clear Cell Sarcoma of Soft Tissue Trial in Wuhan (18F-PFPN)
Recruiting
- Clear Cell Sarcoma of Soft Tissue
-
Wuhan, Hubei, ChinaChina, Hubei Province
Jul 19, 2023
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- +2 more
- (no location specified)
May 14, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Metastatic Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody
Recruiting
- Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
- AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Sep 12, 2023
Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1
Not yet recruiting
- Metastatic Clear Cell Renal Cell Carcinoma
- With Positive PSMA Expression at Tumor Sites
- 177Lu-PSMA-1 (radiopharmaceutical)
- (no location specified)
Sep 26, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 28, 2023
Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)
Not yet recruiting
- Ovarian Neoplasms
- +5 more
- Dostarlimab
- +4 more
- (no location specified)
Sep 3, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104)
Completed
- Clear Cell Renal Cell Carcinoma
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Feb 6, 2023
Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)
Available
- Clear Cell Renal Cell Carcinoma
- 89Zr-DFO-girentuximab
-
Los Angeles, CaliforniaUCLA
Oct 12, 2023
Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)
Recruiting
- Ovarian Clear Cell Carcinoma
- Gynecologic Cancer
-
Boston, MassachusettsDana Farber Cancer Institute
Oct 13, 2022
Clear Cell Sarcoma Trial in El Segundo, Houston (AMG 337)
Terminated
- Clear Cell Sarcoma
- AMG 337
-
El Segundo, California
- +1 more
Dec 9, 2022
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute
Not yet recruiting
- Advanced Clear Cell Renal Carcinoma (Ccrcc)
- Papillary Renal Cell Carcinoma (Prcc)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Non-Clear Cell Renal Cell Carcinoma Trial in Duarte (XL092, Nivolumab, Sunitinib Malate)
Recruiting
- Non-Clear Cell Renal Cell Carcinoma
- XL092
- +2 more
-
Duarte, CaliforniaExelixis Clinical Site #1
Jan 13, 2023
Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)
Not yet recruiting
- Renal Cell Carcinoma
- Pucotenlimab Combined With Lenvatinib
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen University Cancer Center
Nov 10, 2023
Advanced Cancer, Clear Cell Renal Cell Carcinoma Trial in Houston (177Lu girentuximab, Nivolumab, Cabozantinib)
Not yet recruiting
- Advanced Cancer
- Clear Cell Renal Cell Carcinoma
- 177Lu girentuximab
- +3 more
-
Houston, TexasMD Anderson Cancer Center
Dec 15, 2022